SCHEMBL7189974

SCHEMBL7189974

CCOCCOc1ccc(PC(=O)c2c(OC)cc(OC)cc2OC)c(C)c1.[LiH]

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.39
APP P05067 2/20 0.39
FFAR1 O14842 4/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
CYP3A4 P08684 3/20 0.36
USP2 O75604 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HPGD P15428 1/20 0.36
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
KDM4E B2RXH2 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
THRA P10827 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7174730 0.91 LMNA (0.42) KMT2AAPPFFAR1L3MBTL1MAPK1
SCHEMBL7178251 0.91 KMT2A (0.40) KMT2AAPPL3MBTL1CYP3A4USP2
SCHEMBL7186863 0.90 KMT2A (0.41) KMT2AFFAR1L3MBTL1CYP3A4USP2
SCHEMBL7182358 0.90 KMT2A (0.41) KMT2AL3MBTL1CYP3A4USP2MAPK1
SCHEMBL7175230 0.90 THRA (0.42) KMT2AL3MBTL1CYP3A4USP2MAPK1
SCHEMBL7180950 0.90 KMT2A (0.42) KMT2AL3MBTL1CYP3A4USP2MAPK1
SCHEMBL7180616 0.88 THRA (0.45) KMT2ATHRA
SCHEMBL7175053 0.87 THRA (0.47) THRA
SCHEMBL7177891 0.85 FFAR1 (0.42) APPFFAR1L3MBTL1SMN1; SMN2LMNA
SCHEMBL7183202 0.85 MAPK1 (0.40) KMT2AL3MBTL1CYP3A4USP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885APP 4723/4885FFAR1 671/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885APP 4740/4885FFAR1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.